JP2013536408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013536408A5 JP2013536408A5 JP2013518767A JP2013518767A JP2013536408A5 JP 2013536408 A5 JP2013536408 A5 JP 2013536408A5 JP 2013518767 A JP2013518767 A JP 2013518767A JP 2013518767 A JP2013518767 A JP 2013518767A JP 2013536408 A5 JP2013536408 A5 JP 2013536408A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- maximum threshold
- less
- item
- statin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 76
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 32
- 239000008280 blood Substances 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 14
- 102000000802 Galectin 3 Human genes 0.000 claims description 12
- 108010001517 Galectin 3 Proteins 0.000 claims description 12
- 206010019280 Heart failures Diseases 0.000 claims description 5
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 claims description 4
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 claims description 4
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 4
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 4
- 229960005370 atorvastatin Drugs 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 229960000672 rosuvastatin Drugs 0.000 claims description 4
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 3
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims description 2
- 101000608757 Homo sapiens Galectin-3 Proteins 0.000 claims description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 2
- 229940123934 Reductase inhibitor Drugs 0.000 claims description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 2
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 229960005110 cerivastatin Drugs 0.000 claims description 2
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims description 2
- 229960003765 fluvastatin Drugs 0.000 claims description 2
- 102000048551 human LGALS3 Human genes 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 229960004844 lovastatin Drugs 0.000 claims description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 2
- 229950009116 mevastatin Drugs 0.000 claims description 2
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims description 2
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 229960002797 pitavastatin Drugs 0.000 claims description 2
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 229960002965 pravastatin Drugs 0.000 claims description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 229960002855 simvastatin Drugs 0.000 claims description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 37
- 102000007563 Galectins Human genes 0.000 claims 1
- 108010046569 Galectins Proteins 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36121610P | 2010-07-02 | 2010-07-02 | |
| US61/361,216 | 2010-07-02 | ||
| PCT/US2011/042846 WO2012003475A1 (en) | 2010-07-02 | 2011-07-01 | Statin therapy monitored by galectin- 3 measurement |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013536408A JP2013536408A (ja) | 2013-09-19 |
| JP2013536408A5 true JP2013536408A5 (enExample) | 2014-08-07 |
Family
ID=44628757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013518767A Pending JP2013536408A (ja) | 2010-07-02 | 2011-07-01 | ガレクチン−３測定によりモニタリングされるスタチン療法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20120029003A1 (enExample) |
| EP (1) | EP2588111A1 (enExample) |
| JP (1) | JP2013536408A (enExample) |
| WO (1) | WO2012003475A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2742265C (en) * | 2008-10-29 | 2014-07-15 | Bg Medicine, Inc. | Galectin-3 immunoassay |
| KR20120104167A (ko) * | 2009-08-25 | 2012-09-20 | 비쥐 메디신, 인코포레이티드 | 갈렉틴―3 및 심장 재동기화 요법 |
| WO2013169890A1 (en) * | 2012-05-08 | 2013-11-14 | Bg Medicine, Inc. | Systems and methods for assessing disease risk, status, and prognosis |
| EP2843414B1 (en) | 2013-08-26 | 2018-09-19 | Roche Diagniostics GmbH | Marker for statin treatment stratification in heart failure |
| ES2712201T3 (es) | 2014-01-28 | 2019-05-09 | Hoffmann La Roche | Biomarcadores para la evaluación de riesgos y la monitorización del tratamiento en pacientes de insuficiencia cardíaca que han recibido terapia guiada por el péptido natriurético de tipo B |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4632901A (en) | 1984-05-11 | 1986-12-30 | Hybritech Incorporated | Method and apparatus for immunoassays |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| AU2684488A (en) | 1988-06-27 | 1990-01-04 | Carter-Wallace, Inc. | Test device and method for colored particle immunoassay |
| US20010051350A1 (en) | 1995-05-02 | 2001-12-13 | Albert Nazareth | Diagnostic detection device and method |
| CA2293718A1 (en) | 1997-06-10 | 1998-12-17 | Medlyte Diagnostics, Inc. | Methods for early detection of heart disease |
| WO2004111654A2 (en) * | 2003-06-06 | 2004-12-23 | Ciphergen Biosystems, Inc. | Serum biomarkers in ischaemic heart disease |
| EP1522857A1 (en) * | 2003-10-09 | 2005-04-13 | Universiteit Maastricht | Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
| DK1718967T3 (da) * | 2004-02-03 | 2013-06-03 | Diadexus Inc | Metoder til at detektere Lp-PLA2 aktivitet |
| US9934294B2 (en) | 2014-09-26 | 2018-04-03 | Wal-Mart Stores, Inc. | System and method for using past or external information for future search results |
-
2011
- 2011-07-01 WO PCT/US2011/042846 patent/WO2012003475A1/en not_active Ceased
- 2011-07-01 US US13/175,523 patent/US20120029003A1/en not_active Abandoned
- 2011-07-01 EP EP11734227.9A patent/EP2588111A1/en not_active Withdrawn
- 2011-07-01 JP JP2013518767A patent/JP2013536408A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| S Antonopoulos et al. | Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials | |
| JP2015503588A5 (enExample) | ||
| Muramatsu et al. | Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin | |
| JP2013536408A5 (enExample) | ||
| JP2016517883A5 (enExample) | ||
| IL292829A (en) | Fixed dose combinations containing etc1002 and one or more statins to treat or reduce cardiovascular risk | |
| JP2018508551A5 (ja) | 心血管疾患を処置するか又は心血管疾患のリスクを低減させるためのｅｔｃ１００２及び１種以上のスタチンを含む固定用量組合せ物 | |
| AU2009246603A8 (en) | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction | |
| Rogers et al. | A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin | |
| JP2012505905A5 (enExample) | ||
| Stein | Management of dyslipidemia in the high-risk patient | |
| Stepien et al. | Role and significance of statins in the treatment of hypertensive patients | |
| JP2002525321A5 (ja) | カテーテルによる血管再生を予防または遅らせる医薬組成物の製造のためのコレステロール低下剤の使用 | |
| JP4839309B2 (ja) | 血栓症治療剤 | |
| RU2018133690A (ru) | Лечение пациентов с гомозиготной семейной гиперхолестеринемией, получающих липидоснижающую терапию | |
| Sanfelice et al. | Activity of rosuvastatin in tachyzoites of Toxoplasma gondii (RH strain) in HeLa cells | |
| Tan et al. | Do Singapore patients require lower doses of statins? The SGH Lipid Clinic experience | |
| RU2003113328A (ru) | Профилактическое и терапевтическое средство для лечения осложнений, связанных с диабетом | |
| Switzer et al. | Statin therapy for coronary heart disease and its effect on stroke | |
| JPWO2006011495A1 (ja) | 高コレステロール血症及び／又は高トリグリセリド血症治療剤 | |
| TW201219037A (en) | Prophylactic and/or therapeutic agent against lymphedema | |
| Rembold | To statin or to non-statin in coronary disease—considering absolute risk is the answer | |
| NZ603397A (en) | Association of xanthine oxidase inhibitors and statins and use thereof | |
| B Alonzo | Myths and facts concerning the use of statins in very old patients | |
| Pedersen | Intensive lipid-lowering therapy for patients with aortic stenosis |